Estradiol plays an important role in the regulation of **adipose tissue distribution and adipocyte function** and in the **regulation of glucose and lipid metabolism in liver and skeletal muscle**. Estradiol deficiency (e.g. menopause) is associated with increased adiposity and insulin resistance, while estradiol replacement can reverse many of these metabolic changes. However, this review does not identify skeletal muscle as a primary site of **estrogen clearance or elimination**; estrogen metabolism and excretion occur mainly via hepatic conjugation and biliary/renal pathways.

The review notes that estrogens "have a role in maintaining muscle mass" and that when estrogen is deficient, as in advanced age in females, there is a decline in skeletal muscle mass and strength (sarcopenia). It explains that estradiol acts on muscle through estrogen receptors and affects muscle regeneration and metabolism. However, the article focuses on how estrogen levels affect muscle, not on muscle mass affecting estrogen clearance or elimination.

Men in the highest tertile of estradiol-to-testosterone ratio (E2:T) had the highest spine BMD, highest truncal fat, and lowest truncal lean body mass. Fat mass significantly increased, whereas lean mass significantly decreased with increasing E2:T tertiles. The authors state: "A male with high aromatase activity may be able to maintain an adequate bone mass but may suffer from low muscle mass, and vice versa." This links higher estrogen relative to testosterone with lower muscle mass, but does not say muscle mass controls estrogen elimination.

In this clinical study, the authors report that postmenopausal women had significantly higher estradiol levels when they had higher fat mass, and that estradiol levels were more closely related to adipose tissue than to lean mass. They describe adipose tissue as an important site of aromatization of androgens to estrogens, which can maintain or increase estrogen levels in women with higher body fat. The paper does not describe skeletal muscle mass as a determinant of estrogen elimination; rather, it emphasizes fat mass and aromatase activity as key for circulating estrogen levels.

This review notes that in postmenopausal women and men, estradiol is mainly produced by aromatase in adipose tissue converting testosterone to estradiol. It states that estrogen is "clearly beneficial for muscle mass and strength" in animal models, and that estrogen improves muscle proteostasis, but also that high estrogen levels can decrease power and performance and increase injury risk. The focus is on how estrogen affects muscle, not on muscle mass as a determinant of estrogen clearance from the body.

“The liver is a major target organ of estrogen action and a key player in the regulation of lipid and glucose homeostasis… Estrogen deficiency leads to adverse systemic metabolic changes in skeletal muscle, adipose, and the gut, which further promote the MASLD phenotype.” The review describes how **estrogen levels affect liver metabolism**, but does not state that low skeletal muscle mass slows hepatic estrogen clearance; instead, it frames the liver as responding to estrogen status.

The authors used estrogen receptor and aromatase knockout mice to study estrogen deficiency. They report that "loss of aromatized E2 resulted in a large body mass increase with a concomitant increase in muscle size such that muscle mass normalized to body mass was comparable with wild-type mice." They also state that E2 effects on skeletal muscle are complex and may be mediated via ERα and other mechanisms. This paper examines effects of estrogen and aromatase on muscle mass rather than showing that lower muscle mass impairs estrogen elimination.

This systematic review of 12 studies (4474 postmenopausal women) concludes that estrogen-based hormone therapy users lost 0.06 kg less lean body mass than controls, but the difference was not statistically significant. The focus is on how exogenous estrogen therapy may influence lean mass; the paper does not present evidence that varying muscle mass changes estrogen clearance. Instead, it treats hormone therapy as influencing muscle, not muscle influencing estrogen pharmacokinetics.

This review describes that the liver is the principal site for estrogen metabolism: estrogens undergo oxidation, conjugation (sulfation and glucuronidation), and are then excreted in bile or urine. It explains that hepatic function and expression/activity of metabolic enzymes (such as cytochrome P450s and UDP-glucuronosyltransferases) are key determinants of estrogen clearance. The article does not implicate skeletal muscle mass as a limiting factor in estrogen elimination; the major organs involved are the liver, intestines, and kidneys.

Skeletal muscle is the largest organ in the body by mass and plays a central role in whole-body **glucose and lipid metabolism**. It is responsible for the majority of insulin-stimulated glucose uptake and is a major site of fatty acid oxidation. The article describes muscle as an important metabolic sink for glucose and lipids, but it does not attribute to skeletal muscle a major role in **steroid hormone (e.g., estrogen) clearance**, which is instead governed largely by hepatic and renal pathways.

This review explains that aromatase is expressed in various tissues but that "adipose tissue is a major site of estrogen biosynthesis in both men and postmenopausal women" because of its high aromatase expression. It notes that with increasing adiposity, circulating estrogen levels can rise due to increased peripheral conversion of androgens to estrogens in fat. The article discusses estrogen production and metabolism largely in adipose tissue, not in skeletal muscle, and does not indicate that lower muscle mass directly reduces estrogen clearance.

The authors engineered a mouse model with increased aromatase in muscle: “SkM-Arom↑ significantly increased E2 in skeletal muscle, circulation, the liver, and adipose tissue.” They conclude: “Endogenous production of skeletal muscle E2 has a profound antiobesity effect in males without causing skeletal muscle catabolism.” This paper shows that skeletal muscle can **produce estrogen** and influence systemic levels, but it does not indicate that low muscle mass impairs estrogen clearance; rather, more muscle aromatase increases estrogen exposure.

The review states that estrogens are produced in ovaries and, in men and postmenopausal women, mainly in extragonadal tissues like adipose tissue via aromatase. It emphasizes that "the liver is the major site of estrogen metabolism" involving hydroxylation and conjugation, and notes that obesity and adipose tissue influence circulating estrogen levels. There is discussion of body composition (obesity vs leanness) on estrogen levels, but nothing indicating that low skeletal muscle mass specifically makes it harder to eliminate estrogen.

The review notes: “Adipose tissue is an important source of estrogens in both men and women due to aromatase activity… Obesity-associated increase in adipose aromatase can result in higher circulating estrogens, which may impact cardiometabolic risk.” It focuses on **adipose tissue as a site of estrogen production** and metabolic effects, not on skeletal muscle mass determining estrogen elimination capacity.

In this cross-sectional study of postmenopausal women, the authors report that total and trunk fat mass were positively associated with serum estradiol concentrations, whereas lean mass was not a significant independent predictor after adjusting for fat mass. They conclude that "fat mass, but not lean mass, is the main body composition determinant of serum estradiol" in this population. This suggests that higher fat mass is more important than muscle mass for circulating estrogen levels; the study does not claim that lower muscle mass impairs estrogen elimination.

This article outlines the pathways of estradiol metabolism, emphasizing phase I hydroxylation (e.g., 2- and 4-hydroxylation) and phase II conjugation (glucuronidation, sulfation) largely in the liver. It notes that these reactions increase water solubility, allowing metabolites to be excreted in urine and bile. The pathways described are enzymatic and hepatic; no role is attributed to the amount of skeletal muscle mass in controlling the rate of estradiol elimination.

Reporting on a Cell Reports study, this article states that estradiol deficiency "not only reduces muscle mass but also compromises post-injury recovery capacity" by reducing the number and function of muscle stem cells. The research shows a causal direction from low estrogen to poorer muscle stem cell maintenance and muscle atrophy. It does not say that having low muscle mass in itself makes it more difficult for the body to eliminate estrogen; rather, estrogen levels are influencing muscle characteristics.

The chapter notes that approximately **75% of whole‑body glucose disposal occurs in skeletal muscle**, and that estrogens modulate insulin sensitivity and glucose uptake in this tissue. It explains that estrogen receptors in skeletal muscle influence glucose transport and oxidation, thereby affecting systemic energy homeostasis. The focus is on how **estrogen acts on muscle** to regulate metabolism; the text does not state that muscle mass materially determines estrogen elimination from the body.

Estrogens regulate glucose metabolism and energy homeostasis in multiple tissues including the **liver, skeletal muscle, adipose tissue, and pancreas**. The review details how estrogens improve insulin sensitivity, modulate mitochondrial function, and affect substrate utilization in these organs. Estrogens are described as modulators of muscle metabolism and inflammation, but the article reiterates that **hepatic metabolism and conjugation** are the main pathways for estrogen clearance from circulation.

In this cohort of middle-aged and older men, the authors examined associations of body composition with sex steroids. They found that fat mass was positively related to estradiol levels, while lean mass had weaker or no independent association after accounting for fat mass. They note that adipose tissue is a major site of aromatization, explaining the link between fat and estradiol; the data do not show that lower muscle mass hampers estrogen clearance.

Scientists at Salk report that **estrogen-related receptors (ERRs)** play an important role in muscle cell metabolism, especially during exercise. They found that when muscles need more energy, ERRs increase the number and activity of mitochondria in muscle cells, enhancing energetic output. These receptors are described as drivers of mitochondrial growth and activity in skeletal muscle, illustrating how **estrogen-related signaling influences muscle metabolism**, but the article does not claim that muscle mass determines the body's ability to eliminate estrogen.

Reporting on work from the University of Jyväskylä, the article states: “Estrogen acts as a regulator of muscle energy metabolism and muscle cell viability… Menopause leads to the cessation of ovarian estrogen production, which is associated with loss of muscle mass and strength.” The findings describe how **low estrogen contributes to muscle loss**, not the reverse idea that low muscle mass limits the body’s ability to eliminate estrogen.

Sarcopenic obesity is characterized by the **coexistence of low muscle mass and high fat mass**, which is associated with insulin resistance, chronic inflammation, and increased cardiometabolic risk. The review notes that adipose tissue acts as an endocrine organ, secreting adipokines and serving as a site of sex steroid metabolism, including estrogen. While changes in body composition alter hormone profiles through increased adipose aromatase activity and inflammatory signaling, the paper does not identify low muscle mass per se as a factor that directly impairs **estrogen clearance**.

From standard human physiology texts and endocrinology reviews, estrogen clearance is understood to be primarily hepatic and renal: estrogens are metabolized in the liver via cytochrome P450 enzymes and conjugation pathways, then excreted in bile and urine. Skeletal muscle is a major site of glucose uptake and influences overall metabolic rate and insulin sensitivity, but it is not considered a primary organ for estrogen metabolism or excretion. While having more muscle might slightly increase total metabolic clearance for many compounds, there is no widely cited core physiology or pharmacokinetics reference that identifies low skeletal muscle mass as a key limiting factor for the body's ability to eliminate estrogen.